₹1,286.15 61.20 (5.00%)
04:01 PM, 5-Mar-2025₹1,284.70 61.15 (5.00%)
03:53 PM, 5-Mar-2025BSE : 532300
NSE : WOCKPHARMA
Sector : Health care
ISIN Code : INE049B01025
Last Updated: 05-Mar-2025 | 04:01 PM IST
Market Cap (₹ Cr) | 20,897 |
Traded Value (₹ Cr) | 4.60 |
Volume (Shares) | 35,777 |
Face Value (₹) | 5 |
52-Week High (₹) | 1,678.60 |
52-Week High Date | 06-Feb-2025 |
52-Week Low (₹) | 489.20 |
52-Week Low Date | 05-Jun-2024 |
All Time High (₹) | 1,996.06 |
All Time High Date | 12-Mar-2013 |
All Time Low (₹) | 62.20 |
All Time Low Date | 13-Mar-2009 |
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 20,874 |
EPS - TTM (₹) [C] | 0.00 |
P/E Ratio (X) [C] | - |
Face Value (₹) | 5 |
Latest Dividend (%) | 200.00 |
Latest Dividend Date | 17-Nov-2016 |
Dividend Yield (%) | - |
Book Value Share (₹) [C] | 270.47 |
P/B Ratio (₹) [C] | 4.75 |
Scheme Name | Amount Invested (₹ Cr) | No Of Shares | Net Asset (%) |
---|---|---|---|
Bank of India Multi Asset Allocation Fund-Reg (G) | 3.19 | 23,000 | 0.96 |
Bank of India Multi Asset Allocation Fund-Reg (IDCW) | 3.19 | 23,000 | 0.96 |
Bank of India Multi Asset Allocation Fund-Dir (G) | 3.19 | 23,000 | 0.96 |
Bank of India Multi Asset Allocation Fund-Dir (IDCW) | 3.19 | 23,000 | 0.96 |
Bank of India Conservative Hybrid Fund (G) | 0.28 | 2,000 | 0.43 |
Bank of India Conservative Hybrid Fund (IDCW-M) | 0.28 | 2,000 | 0.43 |
Bank of India Conservative Hybrid Fund (IDCW-Q) | 0.28 | 2,000 | 0.43 |
Bank of India Conservative Hybrid Fund (IDCW-A) | 0.28 | 2,000 | 0.43 |
Bank of India Conservative Hybrid Fund - Eco (G) | 0.28 | 2,000 | 0.43 |
Bank of India Conservative Hybrid Fund - Eco (IDCW-M) | 0.28 | 2,000 | 0.43 |
Load more
Date | Broker | Action | Prices(₹) | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High (₹) | 1,227.05 1,284.70 |
Week Low/High (₹) | 1,110.05 1,284.70 |
Month Low/High (₹) | 1,110.05 1,680.00 |
Year Low/High (₹) | 490.15 1,680.00 |
All time Low/High (₹) | 62.20 1,999.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | 4.50% | 4.45% | -1.17% | -0.93% |
1 Month | -22.22% | -22.26% | -5.80% | -5.74% |
3 Month | -10.41% | -10.39% | -9.83% | -9.60% |
6 Month | 17.97% | 17.97% | -10.31% | -11.17% |
1 Year | 121.25% | 121.16% | 0.07% | -0.08% |
3 Year | 302.75% | 302.26% | 35.70% | 37.50% |
Executive Chairman : H F Khorakiwala
Managing Director : Murtaza H Khorakiwala
Executive Director : Huzaifa H Khorakiwala
Independent Director : Tasneem Mehta
Independent Director : Vinesh Kumar Jairath
Non-Exec & Non-Independent Dir : Zahabiya Khorakiwala
Independent Director : Akhilesh Gupta
Independent Director : Amelia Fernandes
Company Sec. & Compli. Officer : Rashmi Mamtura
Independent Director : Ahmad Javed
Registered Office: D-4 MIDC, Chikalthana,Aurangabad.,Maharashtra-431006 Ph: 91-240-6694444
1. What's the Wockhardt Ltd share price today?
Wockhardt Ltd share price was Rs 1,286.15 at 04:01 PM IST on 5th Mar 2025. Wockhardt Ltd share price was up by 5.00% over the previous closing price of Rs 1,224.95. Wockhardt Ltd share price trend:
2. How can I quickly analyse the performance of the Wockhardt Ltd stock?
The performance of the Wockhardt Ltd stock can be quickly analysed on the following metrics:
3. What is the market cap of Wockhardt Ltd?
Wockhardt Ltd has a market capitalisation of Rs 20,897 crore.
4. What is Wockhardt Ltd's 52-week high/low share price?
The Wockhardt Ltd’s 52-week high share price is Rs 1,678.60 and 52-week low share price is Rs 489.20.
5. Is the Wockhardt Ltd profitable?
On a consolidated basis, Wockhardt Ltd reported a loss of Rs -22.00 crore on a total income of Rs 331.00 crore for the quarter ended 2024. For the year ended Dec 2024, Wockhardt Ltd had posted a profit of Rs 20.00 crore on a total income of Rs 729.00 crore.
6. Which are Wockhardt Ltd’s peers in the Health care sector?
Wockhardt Ltd’s top 5 peers in the Health care sector are Piramal Pharma, Gland Pharma, J B Chemicals &, Wockhardt, Pfizer, Astrazeneca Phar, Emcure Pharma.
7. Who owns how much in Wockhardt Ltd?
Key changes to the Wockhardt Ltd shareholding are as follows: